Skip to main content
Fig. 3 | World Journal of Surgical Oncology

Fig. 3

From: Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective

Fig. 3

Survival curves of PDAC patients excluding patients who received postoperative radiotherapy. a Disease-free survivals of the UFS and NAC groups. b Overall survivals of the UFS and NAC groups. c Comparison of the disease-free survivals between the UFS and NAC groups adjusted for the pathologic stage. d Comparison of the overall survivals between the UFS and NAC groups adjusted for the pathologic stage. e Disease-free survivals of the UFS and NAC (GS) groups. f Overall survivals of the UFS and NAC (GS) groups. g Comparison of the disease-free survivals between the UFS and NAC (GS) groups adjusted for the pathologic stage. h Comparison of the overall survivals between the UFS and NAC (GS) groups adjusted for the pathologic stage. PDAC, pancreatic ductal adenocarcinoma; UFS, upfront surgery; NAC, neoadjuvant chemotherapy; GS, gemcitabine plus S-1 (tegafur/gimeracil/oteracil)

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us